Prediction Case File
YouTubeEvaluation Complete

Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community

1 extracted signal · 1 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
09 Oct 2025, 21:49 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Membership: Join my YouTube channel membership and unlock exclusive perks! As a member, you'll get early access to videos to stay ahead with the latest content before anyone else. Investor tier members get access to my spreadsheets, and VIP discord members get access to our private discord community
Source overview

AI-generated source summary

The analysis evaluates UnitedHealth (UNH) using forward price-to-earnings ratios from Fiscal AI and a proprietary discounted cash flow model. It notes UNH's forward P/E of 22 and increase from lows of 14-13 earlier in the year. The DCF model suggests an intrinsic value of $449.17 per share, compared to a current market price of $358.77. The analyst believes the company undervalued, taking into account consistent free cash flow and customer base. The underperformance in 2025 is attributed to a company's misjudgment in estimates for how much it will cost to serve their customers, something correctable by adjusting the pricing policy. The last evaluation, on September 23rd, rated UNH as a buy, risk/reward remain attractive. The analyst acknowledges a business trading at a lower price will provide better opportunity, noting when it was trading at 275/250 or even 285. The analyst considers this a buy, rating to be confirmed.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail